Kornimate/medical-research-clean huggingface dataset:
immersive virtual reality bicycling for persons with parkinson's disease

Conditions: Parkinson Disease

Summary: this study has three objectives about persons with parkinson's disease during bicycling: 1. determine the effect of visual feedback and competition during virtual bicycling on neuromuscular and cardiovascular intensity 2. determine the effect of visual-feedback and competition during virtual bicycling on the user experience of motivation, enjoyment \& perception of exercise intensity 3. determine if attention differs during visual feedback compared to competition virtual bicycling

participants will attend one sessions lasting about 2-3 hours. they will complete movement assessments and questionnaires about physical activity. they will then exercise exercise in three different virtual reality augmented bicycling conditions while wearing a head mounted display (goggles). each of the three conditions will last approximately 8 minutes and will be followed by questionnaires about the participant's experience.

Eligibility criteria:
inclusion criteria: * diagnosis of parkinson's disease following the uk brain bank diagnostic criteria, * hoehn and yahr stages ii-iii, * 45-80 years old, * able to ride a stationary upright bicycle, * able to sign informed consent. exclusion criteria: * have a recent history of severe heart disease, severe lung disease, uncontrolled diabetes, traumatic brain injury or neurological disorder other than parkinson disease, * are unable to follow directions or sign a consent form, * do not have adequate vision or hearing ability to see or hear a television, * have unstable medical condition or musculoskeletal disorder such as severe arthritis, recent knee surgery, hip surgery, or any other condition that the investigators determine would impair the ability to ride the bicycle, * have any other medical condition that prevents bicycling, * have moderate depression (score of 9 or more on gds screening tool).

Keywords: parkinson disease parkinsonian disorders basal ganglia disease brain diseases central nervous system diseases nervous system diseases movement disorders synucleinopathies neurodegenerative diseases
fitmi plus home therapy for stroke patients

Conditions: Cerebral Stroke

Summary: the investigators will investigate the efficacy of a newly developed functional exercise device (fitmi plus) for people in the chronic stage after a stroke compared to the fitmi basic (i.e. without functional exercises). fitmi plus combines objects commonly used during activities of daily living with sensors that can track and record the patient's direction and degree of movement as they perform specific functional tasks described on a computer.


Eligibility criteria:
inclusion criteria: * experienced 1 or more strokes \>6 months prior to enrollment * upper extremity fugl-meyer score \>=15 and \<=55 out of 66 * absence of moderate to severe upper extremity pain (\<= 4 out of 10 on the visual-analog pain scale) * ability to understand the instructions to operate fitmi products exclusion criteria: * lack of concurrent severe medical problems * lack of visual deficits * lack of severe neglect or apraxia * no concurrent enrollment in another therapy study
the effect of qva149 on patient reported dyspnea in moderate to severe chronic obstructive pulmonary disease (copd)

Conditions: Chronic Obstructive Pulmonary Disease

Summary: this study assessed the effect of qva149 on patient-reported dyspnea in moderate to severe chronic obstructive pulmonary disease (copd) patients.

this study used a multi-center, randomized, blinded, double-dummy placebo controlled, three-period crossover design to assess the effect of once daily qva149 q.d vs. placebo and tiotropium 18 μg q.d. in terms of patient reported dyspnea as assessed by baseline dyspnea index (bdi)/transient dyspnea index (tdi)(sac version) in patients with moderate to severe copd.

Eligibility criteria:
inclusion criteria: * patients with moderate to severe stable chronic obstructive pulmonary disease * smoking history of 10 pack years * post-bronchodilator forced expiratory volume in 1 second (fev1) between 30 - 80% * patients must be able to use computer mouse and display * mmrc grade\>2 exclusion criteria: * patients with a history of long qt syndrome * patients with type i or uncontrolled type ii diabetes * patients who have had a copd exacerbation or respiratory tract infection within 6 weeks prior to screening * patients with any history of asthma * patients with pulmonary lobectomy, lung volume reduction surgery, or lung transplantation * patients with concomitant pulmonary disease * patients requiring long term oxygen therapy (\>15 h a day) other protocol-defined inclusion/exclusion criteria may apply.

Keywords: copd dyspnea qva149 tiotropium
the relationship between covid-19 infection in pediatric patients and secondary lymphoid organs

Conditions: Covid19; Immune Deficiency; Tonsillitis; Tonsil Hypertrophy; Adenoiditis; Adenoid Hypertrophy

Summary: we aimed to find out whether the tonsils and nasal tissues of pediatric patients are the main factors that protects the children's immune system against covid-19 infection.

since it is known that the tonsil and adenoid tissues that are known as a secondary lymphoid organ, which form the first line of defense, are more active in childhood than adults, especially in the childhood age group, and since it has been scientifically shown that patients diagnosed with covid-19 infection in the pediatric age group overcome this disease lightly than adults, we aimed to reveal whether the defined tonsil and adenoid tissues are the main factors that protect the children's immune system against covid-19 infection.

Eligibility criteria:
inclusion criteria: * patients with covid-19 infection. * patients aged between 1-16 years * patients whose pcr test becomes negative exclusion criteria: * patients with lymphoid tissue malignant disease * patients with known lung disease * patients with known systemic disease

Keywords: pediatric covid19 i̇mmune system
establishment of a tumor bank for blood samples

Conditions: Ovarian Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Neoplasms of the Female Genitalia; Lung Neoplasms; Endocrine Gland Neoplasms

Summary: establishment of a tumor bank, consisting of blood samples of tumor patients and healthy people as controls. the blood samples will be collected systematically together with the corresponding clinical data. the biological samples, the clinical date together with prospective experimental date constitute the entity of the tumor bank.

recent progress in diagnosis and therapy of cancer diseases can be ascribed mainly to translational research. the relevance of "translational oncology" will only increase in the future -"from bench to bedside" - the swift implementation of new science research results in clinical studies in order to expedite progress in clinical cancer therapy for the benefit of the patient. its almost a matter of course in the medical science today to collect biological samples together with clinical information thereby creating the foundation for future excellent fundamental research. the aim of this tumor bank is to consist of biological samples (together with a tissue bank - see ek 260/2003) and isolates of tumor patients and healthy people as controls. the biological samples, the clinical date together with prospective experimental date constitute the entity of the tumor bank. the content of the tumor bank can provide essential material for current and future research (e.g. analyses of prognostic or predictive tumor markers; genetically analysis (polymorphism, mutation, hypermethylation; verification and characterisation of disseminated tumor cells).

Eligibility criteria:
inclusion criteria: * male/female * age 18 to 90 years max. * just one current known malignant disease or * just one current inflammatory disease exclusion criteria: * inflammatory disease and malignant disease * multiple malignancies * multiple diseases * underage

Keywords: circulating tumor cells ctc tumor marker
a study to evaluate the immunogenicity and safety of biocsl quadrivalent influenza vaccine (qiv) in adults aged 18 years and above.

Conditions: Influenza, Human

Summary: this is a study to assess the immune (antibody) response and safety of a biocsl split virion, inactivated quadrivalent influenza vaccine, in comparison with a us licensed 2014/2015 trivalent influenza vaccine (biocsl tiv-1), and a trivalent influenza vaccine containing the alternate b strain (biocsl tiv-2), in healthy adult volunteers aged 18 years and above.

this multicenter, randomized, double-blinded study was conducted during the 2014-2015 northern hemisphere influenza immunization season to evaluate the non-inferior immune response of biocsl qiv to that of biocsl tiv-1 and biocsl tiv-2 along with safety in healthy male and female adults aged ≥ 18 years. each vaccinated subject had a maximum 25 day on-study period with a six month safety follow-up.

Eligibility criteria:
inclusion criteria: * males or non-pregnant females aged ≥ 18 years at the time of vaccination. * females of child-bearing potential (i.e., ovulating, pre-menopausal, not surgically sterile) must be abstinent or be willing to use a medically accepted contraceptive regimen for the duration of the on-study period. females of child-bearing potential must return a negative urine pregnancy test result prior to vaccination with the vaccine. exclusion criteria: * known hypersensitivity to a previous dose of influenza vaccine or allergy to eggs, chicken protein, neomycin, polymyxin, or any components of biocsl influenza vaccines. * vaccination against influenza in the previous 6 months. * known history of guillain-barré syndrome or other demyelinating disease. * clinical signs of active infection and/or an oral temperature of ≥ 100.4°f (38.0°c). * a clinically significant medical condition. * pregnant or lactating females.
influence of therapeutic hypothermia on resting energy expenditure

Conditions: Cardiopulmonary Resuscitation

Summary: the purpose of this study is the evaluation of the influence of therapeutic hypothermia on resting energy expenditure (ree) in patients after cardiopulmonary resuscitation (cpr). we hypothesized that hypothermia would reduce resting energy expenditure in these patients.

therapeutic hypothermia improves neurologic outcome in patients after cardiopulmonary resuscitation (cpr) because of cardiac arrest. in the present study patients will be cooled to 33 degree celsius after cpr for 24h. to avoid shivering patients will be analgosedated and medically paralysed. analgosedation and relaxation have already shown to reduce oxygen consumption up to 20 % in critically ill patients. in patients with brain injury, who were cooled to 33 degree celsius using a cooling meadow ree could be significantly reduced. in critically ill patients with pyrexia cooling using a cooling meadow ree could be reduced. oxygen consumption was reduced about 14,7% per degree celsius. so far no studies evaluating influence of therapeutic hypothermia on ree in patients after cpr have been published. therefore we plan to measure ree in 25 cooled patients after cpr using indirect calorimetry (deltatrac ii metabolic monitor, datex instrumentarium, helsinki, finland).

Eligibility criteria:
inclusion criteria: * st.p. cpr * indication for therapeutic hypothermia for 24h (33 degrees celsius) exclusion criteria: * contraindication for therapeutic hypothermia

Keywords: cardiopulmonary resuscitation therapeutic hypothermia resting energy expenditure
joint mobilization vs. strengthening exercises on cervical proprioception for nonspecific neck pain

Conditions: Chronic Neck Pain; Nonspecific Neck Pain

Summary: this clinical trial aims to compare the effects of cervical joint mobilization versus cervical strengthening exercises in patients with chronic neck pain. the study will assess neck proprioception, pain intensity, cervical muscle strength, range of motion, and neck disability. the main question it aims to answer is: which treatment is superior, or do they have equal effects after the first session and after the 12th session? participants will: receive either cervical joint mobilization or cervical strengthening exercises for 12 sessions. do not perform any physical therapy treatment outside the trial. visit the clinic three times per week for treatment.

neck pain refers to a type of generalized neck discomfort characterized by mechanical features. this condition is a widespread issue, causing significant levels of pain, disability, and can lead to economical strain. patients suffering from neck pain often experience functional impairments, including weak neck muscles and impaired proprioception. strengthening exercises and cervical joint mobilization offer effective relief of pain and improve disability. exploring the superiority of these techniques in improving cervical proprioception to prevent recurrence is still a vague topic. therefore, this study will investigate the effect of maitland joint mobilization versus cervical strengthening exercises in patients with nonspecific chronic neck pain on neck proprioception, pain intensity, cervical muscles strength, range of motion and neck disability. this is a double-blinded randomized clinical trial with a parallel-group design. twenty-six participants will be allocated randomly to one of two groups. group one (mobilization) will have cervical joint mobilization according to maitland approach. group two (exercises) will perform craniocervical, cervical and axioscapular muscles strengthening exercises. treatment will be provided for 12 sessions. both groups will receive standardized care, including patient education and transcutaneous electrical nerve stimulation.

Eligibility criteria:
inclusion criteria: * 18 to 50 years * pain ≥ 3 months * neck pain on vas ≥ 3/10 * ndi ≥ 5/50 points * zz errors ≥ 9 or the time to complete the task ≥ 28s exclusion criteria: * unilateral headache aggravated by neck movement. * upper extremity symptoms beyond the elbow. * any history of neck trauma including whiplash * recent fractures (last 8 weeks) * cervical surgery (last 3 months) * current neck-related dizziness * known or suspected ves3bular pathology * internal fixation of the cervical spine * physical therapy for the neck (last 3 months)

Keywords: chronic neck pain nonspecific neck pain cervical proprioception cervical mobilization cervical strengthening exercises neck cervical proprioception mobilization manual strengthening pain
phase iib safety and efficacy study of four dose regimens of bay1021189 in patients with heart failure with reduced ejection fraction suffering from worsening chronic heart failure (socrates-reduced)

Conditions: Heart Failure

Summary: objective of the study is to find the optimal dose of the once daily oral soluble guanylate cyclase stimulator (sgc) bay1021189 for phase iii that can be given in addition to standard therapy for heart failure with reduced ejection fraction (hfref).


Eligibility criteria:
inclusion criteria: * worsening chronic heart failure (wchf) requiring hospitalization (or intravenous diuretic treatment for hf without hospitalization) with initiation of study treatment after clinical stabilization * left ventricular ejection fraction (lvef) \<45% by echocardiography at randomization exclusion criteria: * intravenous inotropes at any time after hospitalization

Keywords: worsening heart failure heart failure with reduced ejection fraction
evaluating clinical acceptance of a npwt wound care system

Conditions: Diabetic Foot Ulcer; Pressure Injury; Pressure Ulcer

Summary: determine if use of the medela invia motion npwt system supports acceptable progress towards the goal of therapy when treating patients with a variety of wound types during the evaluation period.

the primary objective of this study is to determine acceptable progress towards the goal of therapy for a diabetic foot ulcers (dfu) and pressure injuries/ulcers (pi/pu) wounds when using the medela invia motion endure npwt system during 4-week study duration. goal of therapy will be defined by the physician according to initial assessment: endpoints (dependent on goal of therapy): * decrease in wound volume * decrease in size of the tunneling area * decrease in size of undermining * decrease in amount of slough * increase in granulation tissue * the wound bed is progressing acceptably towards a transition to another treatment modality such as moist wound healing (mwh), surgical closure, or a flap or graft. \*\*study endpoint will be determined by physician at the time of enrollment, when the goal of therapy is documented\*\* b. secondary objectives * to evaluate the ease of use from clinicians. * to evaluate overall satisfaction from clinicians. c. tertiary objectives * adequate management of the exudate

Eligibility criteria:
inclusion criteria: * adult subjects ≥18 years of age. * signed, informed consent by patient or lar within 72 hours of admission to burn center. * patient is determined to be in need of npwt for treatment of a diabetic foot ulcer, pressure injuries/pressure ulcer. * patient is comfortable (e.g. not in pain) * patient is willing and able to adhere to treatment protocol. exclusion criteria: * patient not willing to comply with f/u clinic visits. * subjects with * necrotic tissue with eschar present * untreated osteomyelitis * non-enteric and unexplored fistulas * malignancy in wound * exposed vasculature * exposed nerves * exposed anastomotic site of blood vessels or bypasses * exposed organs * subjects who, in the opinion of the investigator, may be non-compliant with study schedules or procedures. * patients with concurrent conditions or co-morbidities that in the opinion of the investigator may compromise patient safety or study objectives.
a study of ql1706 combined with chemotherapy in advanced non-small cell lung cancer

Conditions: Non-small-cell Lung Cancer

Summary: this study will evaluate the efficacy and safety of ql1706 when given in combination with bevacizumab, paclitaxel or pemetrexed, and carboplatin in patients with stage iiib/c and stage iv non-small cell lung cancer (nsclc). the study will be conducted in two phases: induction phase and maintenance phase.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed stage iiib/c or iv non-squamous nsclc measurable disease, as defined by recist v1.1 eastern cooperative oncology group performance status of 0 or 1 life expectancy \>=3 months adequate hematologic and organ function exclusion criteria: * history of leptomeningeal disease uncontrolled tumor-related pain uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently) uncontrolled or symptomatic hypercalcemia active or history of autoimmune disease or immune deficiency history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (ct) scan
biological implications of the overlapping phenomenon between childhood schizophrenia and autism spectrum disorders-heterogeneity approach rather than diagnostic boundary

Conditions: Schizophrenia; Autism Spectrum Disorder

Summary: complex diseases such as schizophrenia and autism are heterogeneous in clinical presentation and etiology. this high heterogeneity constitutes the challenges for the clinical diagnosis and etiological research, resulting in that the majority of research findings cannot be replicated in the independent samples. for the high comorbid rate between the diagnoses of schizophrenia and autism spectrum disorders (asd), and the shared neurocognitive deficits, genetic risks, and biological markers between the two disorders, a heterogeneity approach may probably be more promising than to arbitrarily split the two diagnostic categories apart or lump them together for etiological research. in schizophrenia, patients with a very early onset of disease and with preceding neurodevelopmental conditions may imply a different underlying etiology from those with typical onset and without neurodevelopmental conditions. echoing the evidence that in early onset parkinson's disease, park2 (encoding parkin protein) mutations are successfully reported to be as frequent as 49% with an autosomal-recessive mode of inheritance , representing a specific disease entity of parkinson's disease. therefore, it is critical to characterize the clinical phenotypes for this subpopulation of very early onset patients, including their clinical manifestation, disease course, and treatment response, as well as early developmental history and morphological characteristics. these may establish an important base for investigating the etiology and providing adequate clinical care for the heterogeneous syndrome of schizophrenia


Eligibility criteria:
inclusion criteria: * sz group: schizophrenia onset earlier than 12 years old * cos group: schizophrenia onset later than 12 years old * asd group: diagnosed with autism spectrum disorder without schizophrenia * dual group: diagnosed with asd and sz exclusion criteria: * congenital disease * major physical diseases * neurodegenerative disorder * chromosomal aberration